OICHARTS
8 AMThe 8 AM report →

AEON

AEON Biopharma, Inc. · XASE · 131 sessions on record
$0.30▲ +0.04 · +15.8%from $0.26 the session before · Sep 30, 2026 close · end of day
Open
$0.32
High
$0.42
Low
$0.24
Day's range
$0.1869% of the previous close
VWAP
$0.34close −11% from it
Volume, shares
116M9.14× the 20-session average
Traded, $
$39.0M
Trades
146K790 shares per trade
Previous close
$0.26+0.04 to the close
Market cap
$15.0Mat the close of Sep 30
Day range34% of the way up
$0.24$0.42
52-week range11% of the way up
$0.18 Aug 20$1.33 Mar 27

−77% from the high · +69% from the low

Options

No listed options on AEON

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
AEON close over the last 126 sessions, with S&P 500 rebased to the first close0.140.651.16axis spans 759%S&P 500AEONApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 759 percent.

Quarterly results

consolidated · latest filed Aug 12, 2026 · SEC filings

Profit −$1.2M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of AEON on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 12——−$1.2M—-0.02▼ −1.6%S&P 500 +0.7% · −2.3 pp
Mar 2026filed May 14——−$11.8M▼ −230%-0.29▼ −9.9%S&P 500 −1.2% · −8.7 pp
Dec 2025filed Mar 30——−$37.1M▼ −1,900%-5.24▼ −0.5%S&P 500 +2.9% · −3.4 pp
Sep 2025filed Nov 14——−$4.5M—-0.39—not reached
Jun 2025filed Aug 12——−$6.6M▼ −100%-0.60▼ −1.6%S&P 500 +0.7% · −2.3 pp
Mar 2025filed May 14——$9.1M—2.28▼ −9.9%S&P 500 −1.2% · −8.7 pp
Dec 2024filed Mar 24——$2.1M—8.04—not reached
Sep 2024filed Nov 14——−$6.2M—-11.24—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of AEON on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025——−$39.2M▼ −190%-3.95
FY24to Dec 2024——$42.0M—72.93
FY22to Dec 2022——−$52.6M▼ −740%-0.38
FY21to Dec 2021——$8.2M——

Fundamentals

consolidated · filings to Jun 2026 · close $0.30 on Sep 30

market cap $15.0M.

Valuation
Market cap
$15.0Mon Sep 30
Price to earnings
—
Trailing EPS
$-5.94diluted · consolidated · four quarters to Jun 2026
Price to book
—
Book value a share
—
Debt to equity
—
Return on equity
—
Dividend yield
—
Price to sales
—
Shares outstanding
49.9Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
—
Revenue growth, 12 months
—
Revenue 3-year CAGR
—
Profit, trailing 12 months
−$54.6Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
REGNRegeneron Pharmaceuticals Inc$71.24Bon Sep 3019consolidated2.3$758.27
UTHRUnited Therapeutics Corp$23.24Bon Sep 3019consolidated3.6$541.89
RPRXRoyalty Pharma plc Class A Ordinary Shares$22.65Bon Sep 3031consolidated—$58.36
BMRNBioMarin Pharmaceuticals Inc$11.61Bon Sep 30150consolidated1.8$60.00
LQDALiquidia Corporation Common Stock$2.71Bon Sep 3022consolidated14$30.26
ANIPANI Pharmaceuticals, Inc.$1.77Bon Sep 3016consolidated3.0$72.65
STOKStoke Therapeutics, Inc. Common Stock$1.68Bon Sep 30—4.9$26.00
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$995.7Mon Sep 30—2.3$11.70
JBIOJade Biosciences, Inc. Common Stock$893.5Mon Sep 301.7consolidated2.0$14.05
CLYMClimb Bio, Inc. Common Stock$658.8Mon Sep 30—2.8$11.47

Shareholding

SEC Forms 3, 4 and 5

No open-market insider buying or selling in the last 90 days.

Insider tradesSEC Forms 3, 4 and 5 · the latest 10
AEON insider trades
InsiderTradeSharesPriceHeld after
Carter Eric GDirectorgranted · Jun 17, 2026222,684$0.00258,705
FISCHER JOSTDirectorgranted · Jun 17, 2026222,684$0.00489,469
Forth MarcDirectorgranted · Jun 17, 2026222,684$0.00973,231
PALMISANO ROBERT JDirectorgranted · Jun 17, 2026222,684$0.00258,705
Thunen Shelley BDirectorgranted · Jun 17, 2026222,684$0.00258,705
Bencich JohnOfficergranted · Apr 2, 2026754,717$0.00754,717
Oh ChadOfficergranted · Feb 17, 2026862,500$0.00866,564
Oh ChadOfficergranted · Mar 4, 20261,316,872$0.002,183,436
Sy JenniferOfficergranted · Feb 17, 2026575,000$0.00575,251
Sy JenniferOfficergranted · Mar 4, 2026925,925$0.001,501,176

Corporate actions

exchange records

No corporate action on record for AEON yet.

Price history

131 sessions on record · to Sep 30 · end of day

AEON is +8.5% over 20 sessions against the S&P 500's +0.1%, 77% below its 52-week high, realised volatility 130% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $AEON %S&P 500 %Difference pp
120 sessionssince Apr 9$0.83▼ −64%▲ +12%−76
60 sessionssince Jul 7$0.70▼ −57%▲ +2.0%−59
20 sessionssince Sep 1$0.28▲ +8.5%▲ +0.11%+8.4
5 sessionssince Sep 23$0.26▲ +14%▼ −0.67%+14
1 sessionsince Sep 29$0.26▲ +16%▼ −0.21%+16
Averages of the closeclose against each average
5-session average
$0.27close +11% from it
20-session average
$0.26close +15% from it
50-session average
$0.26close +15% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.0414% of the close
Average day's range, 20
$0.0414% of the close
Volume against 20 sessions
9.14×116M vs 18.5M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
130%≈ ±8.1% a session · moved more than that on 4 of 20
Realised volatility, 60
160%≈ ±10% a session · moved more than that on 12 of 60
Beta to S&P 500, 60
2.06moved with S&P 500 on 38 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
7 up · 13 downof 20
Last 60 sessions
22 up · 38 downof 60
Best session, 250
▲ +26%Sep 10
Worst session, 250
▼ −33%Jul 13

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 56% of reported volume on Sep 30, 2026, against 46% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
AEON daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 202639.7M70.4M56.4%
Sep 29, 202663.4K141K45.0%
Sep 28, 2026111K205K54.5%
Sep 25, 2026184K351K52.5%
Sep 24, 2026160K327K48.8%
Sep 23, 2026322K614K52.4%
Sep 22, 202647.3K174K27.1%
Sep 21, 2026110K271K40.6%
Sep 18, 2026471K1.3M36.3%
Sep 17, 2026275K609K45.2%

Filings

SEC EDGAR · newest first
AEON SEC filings
FiledFormReport date
Sep 30, 20268-KSep 30, 2026
Aug 21, 2026SCHEDULE 13G—
Aug 21, 20264Aug 19, 2026
Aug 21, 20263Aug 19, 2026
Aug 12, 202610-QJun 30, 2026
Aug 12, 20268-KAug 12, 2026
Aug 3, 20268-KAug 3, 2026
Jul 23, 20268-KJul 23, 2026
Jul 21, 2026SCHEDULE 13G—
Jul 15, 20268-KJul 13, 2026
Jul 15, 2026424B4—
Jul 13, 2026EFFECT—
Jul 13, 2026S-1MEF—
Jul 9, 2026S-1/A—
Jul 8, 2026S-1—
Jun 22, 20264Jun 17, 2026
Jun 22, 20264Jun 17, 2026
Jun 22, 20264Jun 17, 2026
Jun 22, 20264Jun 17, 2026
Jun 22, 20264Jun 17, 2026
Jun 17, 20268-KJun 17, 2026
May 29, 2026DRS—
May 14, 20268-KMay 14, 2026
May 14, 202610-QMar 31, 2026
May 14, 20268-KMay 14, 2026

About AEON Biopharma, Inc.

SEC and exchange records
Company
AEON Biopharma, Inc.
Exchange
XASE
Industry
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1837607
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 08:16 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.